Business
IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million
EVRY, France, July 02, 2025--Regulatory News: IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024.
About this update from Integragen Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2537,"height":762,"url":"https://media.zenfs.com/en/business-wire.com/317a5759047f343ae2e09efe8b6b94c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v1T4tjws6wU6MVHIkEx2CA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/317a5759047f343ae2e09efe8b6b94c5","width":960,"height":288},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EM3UN.0FP8YR.XS6hCPn6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/317a5759047f343ae2e09efe8b6b94c5","width":1200,"height":360}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Sequencing activities at Évry down 31%","length":38,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026","length":248,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":379,"olType":false},{"type":"text","content":"EVRY, France, July 02, 2025--(BUSINESS WIRE)--Regulatory News:","length":62,"tagName":"p"},{"type":"text","content":"IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories, announces today its unaudited sales for the first half of 2024.","length":287,"tagName":"p"},{"type":"text","content":"Sales for the first half came to €2,540K, down 34% compared with the first half of 2024 on a like-for-like basis (excluding revenues from the SeqOIA platform), contrary to expectations of weak growth, comparable to that of 2024, as announced by the Company in its press release dated April 29, 2025, on its results for the 2024 financial year.","length":343,"tagName":"p"},{"type":"text","content":"This decline is the result of reduced activity of over 40% on th...